Wynn, G. J., Rammohan, H. S., Stephens, B., Hawkins, N. M., McMurray, J. J.V. and Rodrigues, E. (2008) How many patients with heart failure are suitable for combination ACE inhibitor and candesartan therapy? Journal of Cardiac Failure, 14(6), S114. (doi: 10.1016/j.cardfail.2008.06.397)
Full text not currently available from Enlighten.
Abstract
Background: Adding candesartan to ACE inhibitor therapy significantly reduced cardiovascular deaths and heart failure (HF) hospitalisations in the CHARM-Added trial. Many clinicians have not adopted this approach due to concerns that real-life patients differ from trials and are at greater risk of adverse events, particularly hyperkalaemia.<p></p> Methods: All referrals to the HF service of a large urban hospital in 2007 were included. Information was collected retrospectively from electronic patient records. We examined how many patients fulfilled CHARM-Added inclusion criteria and had predictors of hyperkalaemia, identified by analysis of that biochemical abnormality in the trial. <p></p> Results: Of 409 referrals, 194 fulfilled CHARM-Added enrolment criteria. With the exception of age, their characteristics and treatments were comparable to participants in CHARM-Added (Table). Predictors of hyperkalaemia were common (72% overall). Raised potassium (13%) and creatinine (7%) were similar to CHARM but advanced age (45%) and spironolactone use (30%) were notably more frequent.<p></p>
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | McMurray, Professor John |
Authors: | Wynn, G. J., Rammohan, H. S., Stephens, B., Hawkins, N. M., McMurray, J. J.V., and Rodrigues, E. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | Journal of Cardiac Failure |
Publisher: | Elsevier |
ISSN: | 1071-9164 |
ISSN (Online): | 1532-8414 |
University Staff: Request a correction | Enlighten Editors: Update this record